Design Therapeutics to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Design Therapeutics (Nasdaq: DSGN) announced management will participate in two investor fireside chats in early December 2025: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 3:30 p.m. ET in New York and Evercore 8th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:00 a.m. ET in Coral Gables, Florida.
Live webcasts will be available on the company’s investor site at www.designtx.com and will be archived for at least 30 days after each presentation.
Details
News Market Reaction – DSGN
On Nov 26, the day this news came out, DSGN closed 0.43% below the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Key Figures
- Piper Sandler conference time
- 3:30 p.m. ET
- Piper Sandler 37th Annual Healthcare Conference on December 3, 2025
- Evercore conference time
- 10:00 a.m. ET
- Evercore 8th Annual Healthcare Conference on December 4, 2025
- Webcast archive period
- 30 days
- Minimum period webcasts remain available after each presentation
Historical Context
-
Announcement of two December investor fireside chats with webcast access.
-
DT-818 nomination, ex-US clearance, multiple trials with 2026–2027 data timelines and cash update.
-
Addition of experienced biotech executive Justin Gover to board, replacing departing director.
-
Fireside chat at 2025 Cantor Global Healthcare Conference with archived webcast.
-
GeneTAC program progress, RESTORE-FA and DT-168 trial updates, and Q2 2025 financial figures.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences:
- Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NY
- Evercore 8th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:00 a.m. ET in Coral Gables, FL
Live webcasts of each fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing DT-818 for myotonic dystrophy type-1, and a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.